References
- Thomas J, Wang L, Clark RE, Pirmohamed M. Active transport of imatinib into and out of cells: implications for drug resistance. Blood 2004;104:3739–3745.
- Crossman LC, Druker BJ, Deininger MW, Pirmohamed M, Wang L, Clark RE. hOCT 1 and resistance to imatinib. Blood 2005;106:1133–1134; author reply 1134.
- Wang L, Giannoudis A, Lane S, Williamson P, Pirmohamed M, Clark RE. Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia. Clin Pharmacol Ther 2008;83:258–264.
- Labussiere H, Hayette S, Chabane K, et al. Pharmacogenomic factors such as the expression of imatinib transporters (OCT-1, ABCB-1 and ABCG-2) at diagnosis, OCT-1 SNPs, and steady-state imatinib and desmethyl-imatinib trough plasma levels in de novo chronic phase chronic myelogenous leukemia, may influence disease response to imatinib. Blood 2008;112(Suppl. 1): Abstract 2643.
- Iraci N, Soverini S, Gherardi S, et al. Expression profiling of ABC transporter genes in chronic myeloid leukemia (CML) and responsiveness to imatinib. Blood 2008;112(Suppl. 1): Abstract 3193.
- Hatziieremia S, Jordanides NE, Holyoake TL, Mountford JC, Jorgensen HG. Inhibition of MDR1 does not sensitize primitive chronic myeloid leukemia CD34+ cells to imatinib. Exp Hematol 2009;37:692–700.
- Racil Z, Razga F, Buresova L, et al. The assessment of human organic cation transporter 1 (hOCT1) mRNA expression in patients with chronic myelogenous leukemia is affected by the proportion of different cells types in the analyzed cell population. Am J Hematol 2010;85:525–528.